Editorial Board ::: Current Drug Metabolism

ISSN: 1875-5453 (Online)
ISSN: 1389-2002 (Print)


Volume 18, 12 Issues, 2017


Download PDF Flyer




Current Drug Metabolism

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 125th of 289 in Biochemistry & Molecular Biology
  • 82nd of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michael Sinz
Bristol Myers Squibb
Wallingford, CT
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.659
5 - Year: 3.064

Editorial Board

Editor-in-Chief:

Michael Sinz (Biography
Michael Sinz

Michael W. Sinz, Ph.D. is Director of Metabolism and Pharmacokinetics at Bristol Myers Squibb where he manages ADmezME lead optimization in drug discovery. Dr. Sinz previously held the position of Section Director-Pharmacokinetics and Drug Metabolism for Parke-Davis/Pfizer. He received B.S. degrees in Chemistry (ACS) and Biology from the University of Wisconsin-Eau Claire and a Ph.D. in Pharmacognosy/Medicinal Chemistry from the University of Minnesota (2001). He is editor in chief of Current Drug Metabolism and associate editor of Drug Metabolism Letters. Dr. Sinz’s resume includes an extensive number of peer reviewed publications, book chapters, and external presentations both locally and internationally.

)

Bristol Myers Squibb
Wallingford, CT
USA



Co-Editor:

Amin Rostami-Hodjegan (Biography
Amin Rostami-Hodjegan

Amin is a Professor of Systems Pharmacology at the Centre for Applied Pharmacokinetic Research (CAPKR) in the Manchester Pharmacy School at the University of Manchester. He is also the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. Professor Rostami has authored/co-authored over 200 peer-reviewed full articles and serves on the Editorial Boards of several journals. He has been an invited speaker at over 170 national and international meetings and has led a number of hands on workshops in the area of in vitro-in vivo extrapolation as applied to ADME in Drug Development.

)

University of Manchester
Manchester
UK


Associate Editors:

Region: USA
Albert P. Li (Biography
Albert P. Li

Dr. Li (Ph. D., Biomedical Sciences, University of Tennessee) is President and CEO of In Vitro ADMET Laboratories Inc., Columbia, MD. He was previously Senior Fellow, Monsanto Company; CSO, In Vitro Technologies; Research Professor, St. Louis University Medical School, and CEO, Phase 1 Molecular Toxicology. His research is focused on the development and application of human-based in vitro experimental models in the accurate assessment of human drug properties including metabolic fate, drug-drug interactions and drug toxicity. Dr. Li has published over 170 research articles, book chapters, and reviews, and co-edited 5 books. He holds multiple U.S and international patents.

)

In Vitro ADMET Laboratories
Columbia, MD
USA

Shufeng Zhou
University of South Florida
Florida, FL
USA

Region: Europe
Aleksandra Galetin (Biography
Aleksandra Galetin

Dr Galetin is the Associate Professor in the Centre for Applied Pharmacokinetic Research, School of Health Sciences, University of Manchester, UK. She is the recipient of the 2012 ISSX European New Investigator Award and 2015 AAPS Meritorious Manuscript Award. Dr Galetin is appointed on the expert panels such as International Transporter Consortium Committee and AAPS Drug Transport Focus Group Steering Committee. She has published over 65 research papers in highly cited peer reviewed journals (H index 35), received more than 50 invitations to present at international meetings and supervised/mentored over 25 graduate students and postdoctoral research associates.

)

University of Manchester
Manchester
UK

Nico P.E. Vermeulen (Biography
Nico P.E. Vermeulen

Prof. Nico P.E. Vermeulen received a doctorate degree in Chemistry (1975, University of Nijmegen, NL) and a PhD degree in Pharmacology (1980, University of Leiden, NL). He was appointed full professor in Molecular Toxicology at VU University Amsterdam (1985). Currently, he is also Director of AIMMS (Amsterdam Institute for Molecules, Medicines and Systems, at VU University). He is author of > 405 peer reviewed publications and was listed at the ISI HighlyScited.com list (e.g. 2001 and 2014). He is interested in the roles molecular and computational toxicology and drug metabolism can play in drug discovery, development and safety assessment.

)

Vrije Universiteit Amsterdam
Amsterdam
The Netherlands

Region: Asia
Kenichi Fujita (Biography
Kenichi Fujita

Dr. Fujita obtained a Ph.D. from the Graduate School of Pharmaceutical Sciences, Hokkaido University (Sapporo, Japan). Dr. Fujita also holds a Bachelor of Engineering from the School of Engineering, Tohoku University (Sendai, Japan). Currently Dr. Fujita is a Professor in the Institute of Molecular Oncology, Showa University. His present research field is clinical pharmacology in cancer pharmacotherapy. He has published more than 100 scientific publications. Dr. Fujita is currently the Associate Editor of this journal (Current Drug Metabolism).

)

Showa University
Tokyo
Japan

Lee Jia (Biography
Lee Jia

Lee Jia is currently Distinguished Professor, “The China Recruitment Program of Global Experts” (1000-talents plan), and the founder Director, Cancer Metastasis Prevention & Alert Center, Fuzhou University, China, managing 10 cancer metastasis detection and prevention-related projects. Prior to this position, he was the Senior Project Officer with the Developmental Therapeutics Program at the National Cancer Institute, NIH, USA (2002-2012). Before joining the NCI/NIH in 2002, he was Associate Director of Cancer Therapy and Research Center in San Antonio, TX, where he was responsible for translational research, and Associate Member of San Antonio Cancer Institute. He received his Ph.D. degree in Pharmacology from the State University of New York under the supervision of Distinguished Professor, Dr. Robert Furchgott, the 1998 Nobel Laureate. Dr. Jia has contributed >150 original papers to high-impact journals, including Science, Nature, PNAS, Nano Today, Blood. He serves as Associate Editor of CDM and CDL. He is the Fellow of the American Association of Pharmaceutical Scientists (AAPS) and held leadership position with AAPS.

)

Fuzhou University
Fujian
China

Jasminder Sahi (Biography
Jasminder Sahi

Jasminder Sahi obtained a Ph.D. degree (Pharmacognosy, 1991) from Panjab University, India and then participated in a post-doctoral program in the Department of Physiology and Biophysics, University of Illinois at Chicago. Jasminder’s research focus is on transporters and induction of drug metabolizing enzymes, using primary hepatocytes. While her initial forays into transporter research involved ion transport to understand CFTR, at Pfizer she changed her focus to xenobiotic transporters, with the goal of improving drug disposition, delivery and safety. She has worked extensively with hepatic and renal transporters as well as the very challenging blood-brain-barrier. She is an elected member of the ISSX council, a reviewer for six journals and has authored over 40 peer-reviewed publications.

)

Sanofi-Aventis Shanghai
Shanghai
China


Regional Editors:

Region: Middle East
Mohammad Amjad Kamal (Biography
Mohammad Amjad Kamal

Dr. Mohammad Amjad Kamal completed three years U2000 Postdoctoral Fellowship in 2003 from the University of Sydney, School of Molecular and Microbial Biosciences. Currently Dr. Kamal is a Distinguished Adjunct Professor in the King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. He has published more than 260 scientific publications. Dr. Kamal is serving as external examiner for PhD thesis evaluation of various universities and as an EiC/regional/editorial member/guest editor of several reputed scientific journals (mostly published by Bentham Science Publishers) on an honorable basis. Recently, he initiated efforts to establish a “Novel Global Community Educational Foundation” as well.

)

King Abdulaziz University
Jeddah
Saudi Arabia

Editorial Board Members:

S. Akhter
LE STUDIUM Loire Valley Institute for Advanced Studies
France

M. Balazy
New York Medical College
Valhalla, NY
USA

G. Bowers
GlaxoSmithKline
Research Triangle Park, NC
USA

J. Cashman (Biography
J. Cashman

John R. Cashman. Ph.D., President, has more than 30 years experience in biomedical research. In 1997, he founded the Human BioMolecular Research Institute to do fundamental and applied research to address human diseases. Previously, he was at the Seattle Biomedical Research Institute, was Associate Director for the IGEN Research Institute and was Assistant Professor of Pharmaceutical Chemistry at UC San Francisco. He was a postdoc with Professor E.J. Corey (1982-1984). Dr. Cashman received his MS and Ph.D. in Medicinal Chemistry from the University of Kansas (1982) and bachelor degrees in chemistry and biology at the College of Creative Studies, UC Santa Barbara (1977). Dr. Cashman is the author of over 240 research articles, book chapters and patents in drug discovery and evaluation.

)

Human BioMol. Research Inst
San Diego, CA
USA

R. Franklin
Array Biopharma Inc
Boulder, CO
USA

H. Glatt (Biography
H. Glatt

Hansruedi Glatt obtained a Ph.D. in biology from the University of Basle. He was Professor for Toxicology and Pharmacology at the University of Mainz (1987-1994), Professor for Molecular Toxicology at the University of Potsdam (1994-2013) and Head of the Department of Nutritional Toxicology at the German Institute of Human Nutrition (1994-2013). He also teaches in the Master Program in Toxicology at the Charité Berlin (since 2008) and is Senior Professor at the Federal Institute of Risk Assessment (since 2014). He has published nearly 290 articles in scientific journals and 85 book chapters.

)

German Institute of Human Nutrition (DIfE)
Nuthetal
Germany

M. Hu (Biography
M. Hu

Ming Hu, PhD., Professor at University of Houston, is internationally known expert in phase II metabolism and drug bioavailability. His laboratory is devoted to the study of bioavailability. He is especially interested in the study of drug delivery modalities and/or mechanisms that translates into clinical utility. Dr. Hu’s lab deploys a variety of biological model systems to study ADME and PK. He has pioneered the concept of utilizing first-pass metabolism to target drugs to colon without systemic exposure or toxicity. His lab has been supported continually by NIH since 1998. He has published more than 150 papers, book and chapters.

)

University of Houston College of Pharmacy
Houston, TX
USA

J.M. Hutzler (Biography
J.M. Hutzler

Dr. Hutzler earned his Ph.D. in pharmaceutical sciences from West Virginia University under the direction of Dr. Timothy S. Tracy and completed a post doc at Pharmacia Corporation in Kalamazoo, Michigan with Dr. Larry Wienkers. Dr. Hutzler is currently Director of In Vitro Metabolism at Q2 Solutions Bioanalytical and ADME Labs in Indianapolis. Prior to joining Q2 Solutions, Dr. Hutzler was a drug metabolism and pharmacokinetic (DMPK) project lead at Boehringer-Ingelheim Pharmaceuticals in Connecticut, and held a similar project lead position at Pfizer Inc. in St. Louis. With over 14 years of experience in the DMPK field, Dr. Hutzler’s research has included atypical enzyme kinetics for cytochrome P450 enzymes, inhibition SAR of CYP2D6, extrapolation of in vitro data to human clearance predictions, and most recently, aldehyde oxidase. He has published more than thirty articles in peer-reviewed journals and four book chapters.

)

Q2 Solutions
Indianapolis, IN
USA

K. Kassahun
Merck & Co
West Point, PA
USA

C. Liu (Biography
C. Liu

Professor Chang-Xiao Liu graduated from Peking University School of Pharmaceutical Sciences (formerly Beijing Medical College) in 1965. In research career of 50 years, Liu has been committed to the study of drug metabolism/pharmacokinetics and pharmacology, and has particularly outstanding contributions on innovative drugs and compound Chinese medicine formulations. Professor Liu published more than 300 academic articles and 12 books on drug metabolism and pharmacokinetics in English and in Chinese. Now Liu served as a Director of State Key Laboratory of drug delivery technology pharmacokinetics and ISSX China Office. Liu won the Bauhinia Medical Achievement Award (Hong Kong) in 2000, elected Academician of Chinese Academy of Engineering in 2003 and was awarded the Special Contribution Award ISSX in 2013.

)

Tianjin Institute of Pharmaceutical Research
Tianjin
China

C. Prakash
CP Pharma Consulting Principal, Drug Metabolism and Pharmacokinetics
MA
USA

M.J. Rose
CHDI Management Inc
Los Angeles, CA
USA

M.B. Silber
Roche Pharmaceuticals
Palo Alto, CA
USA

B.L. Tekwani
University of Mississippi
Oxford, MS
USA

H. Wang (Biography
H. Wang

Dr. Hongbing Wang, Professor & Program Chair, Experimental and Translational Therapeutics, Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy. Dr. Wang’s research interests including investigation of the molecular mechanisms that govern nuclear receptor‐mediated induction of metabolizing enzymes and drug transporters in humans, metabolism‐based drugdrug interactions, and drug‐induced liver toxicity.

)

University of Maryland School of Pharmacy
Baltimore, MD
USA

J. Xiao (Biography
J. Xiao

Dr. Xiao obtained a doctorate (Ph.D.) in Nutrition from Okayama Prefectural University (Japan) in 2009 and worked as a Humboldtian in Universität Würzburg (Germany) supported by AvH Foundation. Currently Dr. Xiao is an Assistant Professor in University of Macau and a Distinguished Professor in Fujian Agriculture & Forestry University (China). He has published more than 120 scientific publications and is named a 2016 Highly Cited Researcher by Thomson Reuters. Dr. Xiao is currently the Editorial Board Member of Anti-Cancer Agents in Medicinal Chemistry, Frontiers in Pharmacology, Industrial Crops and Products, Phytochemical Analysis, Molecules, Journal of Berry Research, Phytomedicine, Pharmacognosy Magazine.

)

University of Macau
Macau
China

T.B. Andersson (Biography
T.B. Andersson

Tommy B. Andersson (PhD) is a senior principal scientist and Science Director at DMPK cardiovascular and metabolic diseases, AstraZeneca R&D, Gothenburg Sweden, since 2012. He is also appointed associate professor at Department of Physiology and Pharmacology, Section of Pharmacogenetics Karolinska Institutet, Stockholm since 2003. He has over 20 years scientific, management and project experience in several positions within the pharmaceutical industry and academia covering drug metabolism and pharmacokinetics as well as hepatotoxicity in projects from early drug discovery to life cycle management. He is the author of more than 150 peer reviewed scientific publications.

)

AstraZeneca R&D Gothenburg Mİlndal
Gothenburg
Sweden

K. Beaumont (Biography
K. Beaumont

Throughout 33 years in the Pharmaceutical industry, Kevin has worked extensively in the drug metabolism field. His major area of expertise is in the modulation of physicochemistry to affect drug disposition and prediction of human pharmacokinetics. He is author on over 40 peer reviewed publications. Kevin has worked on many Discovery and Development projects throughout his career. He has been responsible for the DMPK input to at least 30 FIH studies as well as 10 Phase II compounds, including 1 marketed agent. Kevin now provides DMPK input to the Rare Disease Research Unit, based in Cambridge Massachusetts.

)

Pfizer Global Research and Development
Kent
UK

J. Caldwell
University of Liverpool
Liverpool
UK

C. Chen (Biography
C. Chen

Dr. Chen and obtained her Ph.D. degree in Biomedical engineering from Huazhong University of Science and Technology of China (1996). She is one of the earliest researchers in the field of nanosafety in China. Dr. Chen currently is a principal investigator at CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety in National Center for Nanoscience and Technology of China. She has authored/co-authored over 150 peer-reviewed papers /book chapters, has more than ten issued patents and finished one ISO standard. She has been awarded the Second Prize of the National Natural Science Awards (2012), China Outstanding Young Female Scientists Awards (2014) and the National Science Fund for Distinguished Young Scholars (2014).

)

National Center for Nanoscience and Technology
Beijing, P. R.
China

H. Gao (Biography
H. Gao

Dr. Huile Gao received his PhD in Pharmaceutics from School of Pharmacy, Fudan University in 2013 under the supervision of Prof. Xinguo Jiang. Then he joined the West China School of Pharmacy, Sichuan University as an Instructor in July 2013 and was promoted to an Associate Professor in July 2014. Dr. Gao’s research interests focus on the design, synthesis, characterization and evaluation of stimuli responsive nanomaterials for drug and imaging probe delivery to improve treatment and diagnosis of human diseases especially tumor and brain diseases. He has published over 80 peer-reviewed articles with an H-index of 28.

)

Sichuan University
Chengdu
China

H. Hao (Biography
H. Hao

Dr. Hao obtained his Ph.D. degree in Drug Metabolism and Pharmacokinetics from China Pharmaceutical University. Currently Dr. Hao is a professor and the dean of School of Pharmacy in China Pharmaceutical University. His research mainly covers the molecular mechanisms of drug disposition and metabolic regulation guided target discovery. He has published more than 120 scientific publications and is currently an editor of this journal.

)

China Pharmaceutical University
Nanjing
China

W.G. Humphreys
Bristol-Myers Squibb
Princeton, NJ
USA

M. Kajbaf (Biography
M. Kajbaf

Dr Mahmud Kajbaf holds a Ph.D. from the University of London, King’s College, Biopharmacy Department in the area of drug metabolism and MSc from Aston University, Birmingham.

Currently Dr Kajbaf is Senior Scientist at Aptuit. He has received several awards and honors, such as: Aptuit CEO Excellence Award, GlaxoSmithKline the psychiatry CEDD Leadership Team Award. He is also on the editorial board for several journals. He has published over 33 research articles related to drug metabolism, in vivo-in vitro correlation, drug-drug interaction, HPLC, NMR and mass spectrometry.

)

GlaxoSmithKline S.p.A., Fleming
Verona
Italy

R. Kim
University of Western Ontario
London, ON
Canada

A.E. Mutlib
Wyeth Research
Collegeville, PA
USA

M.S. Roberts
University of South Australia
Adelaide
Australia

T. Rushmore
Merck Research Laboratories
West Point, PA
USA

P.C. Smith
University of North Carolina
Chapel Hill, NC
USA

J. Turgeon
Université de Montréal
Montréal, Québec
Canada

B. Wong
Wong DMPK Consulting, LLC
Redwood City, CA
USA

W. Xie (Biography
W. Xie

Dr. Xie received his MD from the Peking University Health Science Center and PhD from University of Alabama at Birmingham. He is Professor of Pharmaceutical Sciences and Koslow Endowed Chair in Pharmaceutical Sciences at the University of Pittsburgh School of Pharmacy. Dr. Xie has published more than 150 papers and book chapters. He has been invited to speak for over 160 research conferences and departmental seminars. Dr. Xie is also editorial board member for Molecular Pharmacology, Drug Metabolism and Disposition, and Endocrinology.

)

University of Pittsburgh
Pittsburgh, PA
USA

S.K. Balani (Biography
S.K. Balani

Suresh Balani is in Drug Metabolism and Pharmacokinetics department at Takeda Pharmaceuticals International Co. in Cambridge, MA, currently directing drug development in Gastroenterology and Central Nervous System portfolios. He received his Ph.D. at Queen's University of Belfast, Northern Ireland, U.K., and subsequently worked at National Institutes of Health in Bethesda, MD; Merck Research Labs at West Point, PA; and DuPont Pharmaceuticals at Delaware. He has published over 100 scientific papers and abstracts, and has 10 patents. He is on the Editorial Board of Current Drug Metabolism.

)

Takeda Pharmaceuticals International Company
Cambridge, MA
USA

I. Blair (Biography
I. Blair

Dr. Blair received his Ph.D. in Organic Chemistry in 1971 from Imperial College of Science and Technology, London, under the mentorship of the 1969 Nobel Laureate, Sir Derek H.R. Barton. He was appointed as the A.N. Richards Professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania in 1997 and Director of a new Center for Cancer Pharmacology. In 2002, Dr. Blair was appointed as Vice-Chair of the Department of Systems Pharmacology and Translational Therapeutics. In 2014, he became Director of the Penn Superfund Research and Training Program Center, which is funded by the National Institute for Environmental Health Sciences. Dr. Blair is an expert in the use of mass spectrometric methods for the structural elucidation and quantification of endogenous biomolecules. His current research is involved with the development of biomarkers in order to establish genetic/phenotypes. Dr. Blair is a Fellow of the American Association for the Advancement of Science and the American Association of Pharmaceutical Scientists. He received the 2011 Eastern Analytical Award for Outstanding Achievements in Mass Spectrometry. Dr. Blair is Senior Editor of Future Science Open and is on the editorial boards of Molecular and Cellular Proteomics, Journal of Lipid Research, and Steroids. He has published 380-refereed manuscripts.

)

University of Pennsylvania
Philadelphia, PA
USA

D. Capone
University of Naples Federico II
Naples
Italy

L. Di (Biography
L. Di

Dr. Li Di has about 20 years of experience in the pharmaceutical indus¬try including Pfizer, Wyeth and Syntex. She is currently a research fellow at Pfizer, Groton, CT. Her research interests include the areas of drug metabo¬lism, pharmacokinetics, drug-drug interactions, absorption, transporters, and blood–brain barrier. She has over 120 publications including two books and presented over 80 invited lectures. She is a recipient of the Thomas Alva Edison Patent Award, the New Jersey Association for Biomedical Research Outstanding Woman in Science Award, the Wyeth President’s Award and Peer Award for Excellence.

)

Pfizer Inc.
Groton, CT
USA

E.M.J. Gillam
The University of Queensland
St. Lucia
Australia

P.F. Hollenberg (Biography
P.F. Hollenberg

Paul F. Hollenberg, Ph.D., is a Professor Emeritus of Pharmacology at the University of Michigan Medical School. He received his Ph.D. in Biological Chemistry from the University of Michigan and was a Postdoctoral Fellow at the University of Illinois. He was on the faculty at Northwestern University Medical School, Wayne State University School of Medicine (Chair of Pharmacology), and then at the University of Michigan Medical School where he was Chair for more than 20 years. He has published more than 200 peer-reviewed papers and received more that $29 million in NIH funding as a PI or Co-PI.

)

University of Michigan
Ann Arbor, MI
USA

T. Hussain
University of Houston
Houston, TX
USA

E. Kantharaj (Biography
E. Kantharaj

Ethirajulu Kantharaj currently works at D3, A*STAR, Singapore as Head of Technical, R & D. He is a professional drug discovery & development leader with 21 years of experience in DMPK, CMC and Toxicology and early drug development across therapy areas in both small biotech and large pharmaceutical setting. In D3, he is responsible for all the preclinical development activities starting from preclinical development candidate to IND submissions. He was involved in the preclinical development of several NMEs leading to successful INDs in USA and regulatory submissions in Singapore and Australia enabling start of clinical studies. He also strategized successful regulatory meetings with both US (FDA) and EU (EMA) for seeking agreements on the non-clinical development plans and strategy from pre-IND stages to advanced clinical development stages. Previously, Dr Ethirajulu has worked with S*BIO Pte Ltd, Johnson & Johnson Pharmaceutical Research and Development as team leader, ADME/Tox department and AstraZeneca R&D as Head of DMPK and Bioanalytical Chemistry.

)

R & D Technical, D3, A*STAR
Singapore

J. Kirchheiner
University of Ulm
Ulm
Germany

K.B. Park (Biography
K.B. Park

Professor Kevin Park is currently Professor of Pharmacology and Head of the Institute of Translational Medicine at the University of Liverpool. Professor Park is a Fellow of the Royal College of Physicians, a Fellow of the Academy of Medical Sciences and also a Commissioner on Human Medicines. The over-riding theme of his work is bringing “molecule–to-man” and back again, to enable the prediction of adverse drug reactions based on the chemical structure of the drug and the identification of susceptible individuals. This work has been expanded by using pharmacogenomics and toxicogenomics to link findings in patients to the chemical structure of the drug. The group are now in a position to provide solutions to adverse drug reactions through research in two areas: 1) improved drug design and 2) the delivery of individualised medicines.

)

University of Liverpool
Liverpool
UK

A.D. Rodrigues (Biography
A.D. Rodrigues

Dr. Rodrigues serves as Research Fellow at Pfizer Groton, CT USA. He earned his PhD at Surrey University (Guildford, Surrey, England) and has authored 20 book chapters, over 120 peer-reviewed manuscripts, and presented at over 60 symposia. In 2009, he was inducted as AAPS Fellow. Dr. Rodrigues has served on the Editorial Board of numerous drug metabolism journals, is currently Associate Editor of Xenobiotica, and has edited/co-edited 4 books related to drug interactions and drug metabolism. Dr. Rodrigues is adjunct professor at the University of Rhode Island, School of Pharmacy.

)

Pfizer Inc.
Groton, CT
USA

J.F. Rusling (Biography
J.F. Rusling

James F. Rusling was awarded the B.Sc. in Chemistry from Drexel University in 1969, and Ph. D. from Clarkson University in 1979. He is Professor of Chemistry at University of Connecticut, Professor of Surgery and member of the Neag Cancer Center at University of Connecticut Health Center, and adjunct Professor of Chemistry at National Univ. of Ireland. Galway. Current research includes new cancer diagnostics via detection of biomarker proteins, low-cost 3D printed immunoarrays for point-of-care diagnostics, electrochemical and mass spectrometric arrays for toxicity screening, tumor suppressor gene damage, and fundamental bioelectrochemistry. He has authored more than 380 research papers and several books, and is a musician interested in Irish and American folk styles.

)

University of Connecticut
Storrs, CT
USA

M. Soars (Biography
M. Soars

Dr Soars is a Senior Principal Scientist in the Metabolism and Pharmacokinetics department at Bristol-Myers Squibb in Wallingford CT. He received his Bachelors in biochemistry from the University of Warwick in 1998 and a Phd from the University of Dundee in 2002. From 2002-2003, he completed a postdoctoral fellowship at Eli Lilly where he worked on drug glucuronidation under the supervision of Steve Wrighton. He then moved to AstraZeneca where he worked for 8 years developing and implementing both drug metabolism assays and more recently transporter methodology. Since 2011 Dr. Soars has worked at Bristol –Myers Squibb where he helped develop the transporter strategy in Drug Discovery. Research interests include the prediction of pharmacokinetics and drug-drug interactions for new chemical entities and also the application of drug transporter methodology in early Drug Discovery. Dr Soars has published more than 30 scientific publications and is on the Editorial advisory board for a number of publications including Xenobiotica, Current Drug Metabolism and Drug Metabolism letters.

)

Bristol-Myers Squibb
Wallingford, CT
USA

M. Ulgen (Biography
M. Ulgen

Prof. Dr. Mert Ulgen graduated from Marmara University, Faculty of Pharmacy, Istanbul, Turkey in 1981. He finished his MSc degree at the same department and in 1992, he obtained a PhD degree from University of London, King's College, Biopharmacy Department in the area of Drug Metabolism. He returned to Turkey and became an associated Professor in 1993 and a full professor in 1999 at the same department in the area of Pharmaceutical Chemistry. He has got a number of papers on drug synthesis and in vitro hepatic microsomal metabolism of xenobiotics. He directed a number of MSc and PhD thesis. He retired from Marmara University in June 2009 and he became a full time Professor at Acıbadem University, Vocational School of Health Services in the same year. He has a number of administrative duties. He is also a full time chemistry lecturer. He was Director of Enstitute of Health Sciences in Acıbadem University one term (2013-2016). He established Faculty of Pharmacy at the same University in early 2016 and he is currently dean of Pharmacy. He is also head of "Management in Drug Industry" MSc Program.

)

Acibadem University
Istanbul
Turkey

B. Wu (Biography
B. Wu

Dr. Baojian Wu is a Professor of Biopharmaceutics at Jinan University, Guangzhou, China. He is the receiver of “863 Program Young Scientist” and “the Nature Science Foundation of Guangdong for Outstanding Young Scientist”. His primary research interests are the disposition processes and metabolic regulation of phenolic active compounds derived from traditional Chinese medicines (TCM). Dr. Wu’s group has discovered that efflux transporters (MRPs and BCRP) mediated the excretion transport of phase II metabolites, and surprisingly regulated cellular metabolism of phenolic compounds. He has obtained nine research grants and published over 90 papers in SCI journals such as Biochem Pharmacol, Mol Pharm, Pharm Res and Drug Metab Dispos. Dr. Wu received his Ph.D. at the University of Houston, and completed post-doctoral training at Balor College of Medicine. He is serving on the editorial board for two scientific journals, Xenobiotica and Curr Drug Metab.

)

Jinan University
Guangzhou
China

H. Yamazaki (Biography
H. Yamazaki

Dr. Hiroshi Yamazaki has been Professor of Laboratory of Drug Metabolism and Pharmacokinetics at Showa Pharmaceutical University, Tokyo, Japan since 2005. He received his PhD degree from Osaka University in Japan and was trained at Vanderbilt University, TN, USA in 1994. He was a scientist at Osaka Prefectural Institute of Public Health and an Associate Professor of Kanazawa (1998) and Hokkaido (2001) University. He has authored over 340 publications and has been the recipient of the Japanese Society for the Study of Xenobiotics (JSSX) Award and Fellow. He is a member of several editorial committees and the JSSX President-elect (2016-2017).

)

Showa Pharma University
Tokyo
Japan



Reviewer Panel:

1. J.A.G. Agúndez (Spain)
4. E. Chan (Singapore)
7. B. Chowbay (Singapore)
10. Z. Dvorak (Czech Republic)
13. L.L. Gan (USA)
16. J. Hakkola (Finland)
19. P. Honkakoski (Finland)
22. Z.-Yi. Hu (USA)
25. Y. Jounaidi (USA)
28. T. Károly (Hungary)
31. M. Kranendonk (Portugal)
34. P.H. Marathe (USA)
37. A. McLachlan (Australia)
40. A. Nishikawa (Japan)
43. E. Schuetz (USA)
46. Y.-F. Ueng (Taiwan)
49. E.L. Woodahl (USA)
52. C.-H. Yun (South Korea)
2. P. Anzenbacher (Czech Republic)
5. K.-C. Cheng (USA)
8. C. Collins (USA)
11. A. El-Kadi (Canada)
14. K. Grime (UK)
17. N. Helsby (New Zealand)
20. B. Houston (UK)
23. F. Innocenti (USA)
26. A.S. Kalgutkar (USA)
29. R.A. Kemper (USA)
32. J. Lambert (USA)
35. F. Martel (Portugal)
38. R.P. Meyer (Germany)
41. A. Palotas (Hungary)
44. M.-R. Shiran (Iran)
47. K. Venkatakrishnan (USA)
50. Z Yan (USA)
53. J.Y. Zhang (China)
3. D. Brian (USA)
6. M. Chetty (Australia)
9. M.T. Donato (Spain)
12. D. Fuchs (Austria)
15. J. Gu (China)
18. N. Hewitt (Germany)
21. M. Hu (USA)
24. H. Jeong (USA)
27. M.A. Kamal (Saudi Arabia)
30. G.M. Kirby (Canada)
33. M.-C. Liu (USA)
36. H.H. Maurer (Germany)
39. B. Moorthy (USA)
42. J. Sahi (USA)
45. W. Tang (USA)
48. B. Wong (USA)
51. A.M. Yu (USA)
Advertisement
12th annual ADMET 2017Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals




Related eBooks



Webmaster Contact: info@benthamscience.org Copyright © 2017 Bentham Science